Skip to main content

South Africa: Coronavirus

Question for Foreign, Commonwealth and Development Office

UIN 21806, tabled on 24 June 2021

To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what steps the Government is taking to encourage (a) Pfizer and (b) Moderna to share their mRNA technology with the South African mRNA vaccine technology transfer hub to facilitate regional vaccine manufacturing.

Answered on

30 June 2021

Alongside our G7 partners, the UK is committed to working internationally on efforts to support our ambitious shared goal of vaccinating the world by the end of 2022. This includes efforts to increase vaccine supply by working with suppliers to boost manufacturing, and develop more sustainable approaches to support COVAX as well as wider future pandemic preparedness.

Building vaccine manufacturing capacity is a long term, capital intensive, and high risk endeavour that will require sustained partnerships for supporting viable business models. We are working with the COVAX Supply Chains and Manufacturing Task Force, multilateral, and industry partners to expand quality and affordable vaccine supplies, smooth supply chains, support better information sharing and match making to increase trusted partnerships for manufacturing. The UK has funded McKinsey to scope opportunities for increasing vaccine manufacturing in Africa, and supported the African Union's Africa Manufacturing summit in April this year. We were also the largest funder of Coalition for Epidemic Preparedness Innovations (CEPI) in 2020, which is leading work internationally to increase vaccine manufacturing capacity.